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Announcement
The Charles R. Ream, MD, Award for 
Excellence—2009
One of the most rewarding aspects of my position as the Editor-in-Chief of Current 
Therapeutic Research is to work with the editorial board to determine the winner of the 
annual Charles R. Ream, MD, Award for Excellence. The Ream Award is presented 
each year for one article from the previous year that exemplifies Dr. Ream’s interest in 
randomized controlled trials that try to accomplish important goals. Eligible studies are 
challenging clinical trials carried through with the highest-quality scientific methodology 
and analysis in the service of a worthwhile goal.
I am proud to announce that the 10th Ream Award is being presented to Chu et al1 for 
the manuscript titled, “Efficacy and Safety of Solifenacin Succinate 10 mg Once Daily: 
A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 
Trial in Patients With Overactive Bladder.”
Significant research into the treatment of overactive bladder has been published and 
the efficacy of antimuscarinic agents such as solifenacin succinate has already been well 
established. However, adverse events often limit the use of these agents and current 
guidelines recommend starting with lower doses to minimize these effects, with dose 
escalation as necessary. The authors of this year’s Ream Award winning report have 
performed a well-designed trial attempting to detail the efficacy and tolerability of a 
higher dose (10 mg) in a relatively large cohort of individuals with overactive bladder. 
The results provide reassuring data that most individuals tolerate this increased dose 
and do indeed realize reductions in symptoms.
The strength of this study was in the careful attention to all aspects of study design 
including sample-size determination, randomization, and allocation concealment. The 
authors made every attempt to ensure that bias was avoided in the allocation of treatment 
groups and the reporting of outcomes. However, the manuscript had several limitations 
that also should be noted. First, the authors did not use a true intent-to-treat analysis, 
preferring instead to use an a priori–defined full analysis set. In addition, it is clear from 
the relatively high rates of loss to follow-up that a significant number of individuals did 
not complete the trial. However, data on adverse events are presented for all randomized 
individuals who received at least one dose of study drug. It is notable that the authors 
discuss these and other limitations objectively in the discussion section and carefully 
document how these limitations may have affected the outcomes presented.
It is for these efforts that the manuscript has been chosen as the 2009 recipient of the 
Charles R. Ream, MD, Award for Excellence. Please join me in congratulating the authors 
of this manuscript on their award. The editorial board of Current Therapeutic Research is 
looking forward to another year of exceptional manuscripts from all of our contributors.
Judd L. Walson, MD, MPH
Editor-in-Chief
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